Treatment with nine cycles of tailored FEC with G-CSF support (median cumulative dose of epirubicin was 780 mg/m2) was, however, associated with an increased risk of acute myeloid leukemia and myelodysplastic syndrome. This evidence concerns the gene CSF3 and acute myeloid leukemia.